SlideShare a Scribd company logo
1 of 65
Download to read offline
DRUG INDUCED GINGIVAL
ENLARGEMENT
1
1. Introduction
2. Classification of gingival enlargement
3. Indices for gingival enlargement
4. Drugs associated with gingival enlargement
o Anticonvulsants
o Immunosuppressants
o Calcium Channel blockers
o Miscellaneous
8. Prevalence of drugs causing gingival enlargement
9. Clinical manifestations and Histopathologic features
10. Pathogenesis of Drug induced gingival enlargement
11. Risk factors for Drug induced gingival enlargement
12. Management
13. References
2
Coral PinkScalloped &
Knife edged
Surface Texture
StippledFirm & resilient
consistency
Size : Cellular +
Intercellular + Vasculature
Interdental Papilla
Anterior – Pyramidal
Posterior – Tent shaped
Gingiva in
health…..
3
INCREASE IN SIZE OF GINGIVA
INFLAMMATORY TYPE
Increased cells
Decreased fibers
NON - INFLAMMATORY TYPE
Increased fibers
Decreased cells
4
REASONS FOR INCREASE IN SIZE OF GINGIVA
Accumulation of:
Products of inflammation
Increase in:
Cellular + fibrous + ground
substance
5
Various terms used previously
Gingival
Hyperplasia
Gingival
Hypertrophy
Fibrous gingival
Hyperplasia
Gingival Overgrowth
To denote excessive
gingival proliferation
secondary to drugs
Gingival
Enlargement
Preferred term
6
7
SEQUELAE OF GINGIVAL OVERGROWTH
Aesthetic changes
Difficulty in maintaining good oral hygiene
Clinical symptoms such as pain
Speech disturbances
Abnormal tooth movement
Dental occlusion problem
Enhanced risk of caries & periodontitis
Brunnet et al 1996
8
CLASSIFICATION OF GINGIVAL
ENLARGEMENT
9
• Acute
• Chronic
Inflammatory enlargement
• Drug induced
• Idiopathic
Fibrotic enlargement
• Fibrotic + InflammatoryCombined enlargement
• Conditioned enlargement
• Pregnancy
• Puberty
• Vitamin C Deficiency
• Plasma Cell Gingivitis
• Non Specific Conditioned Enlargement (Granuloma
Pyogenicum)
• Systemic diseases causing gingival enlargement
• Leukemia
• Granulomatous Diseases (Wegner’s Granulomatosis,
Sarcoidosis, etc. )
Enlargements associated
with systemic
diseases/conditions
• Benign Tumors
• Malignant Tumors
Neoplastic Enlargement
(gingival Tumors)
False Enlargement
OLDERCLASSIFICATION
According to etiologic factors
& pathologic changes
10
• Acute
• Chronic
Inflammatory enlargement
Drug induced enlargement
• Conditioned enlargement
• Pregnancy
• Puberty
• Vitamin C Deficiency
• Plasma Cell Gingivitis
• Non Specific Conditioned Enlargement (Granuloma
Pyogenicum)
• Systemic diseases causing gingival enlargement
• Leukemia
• Granulomatous Diseases (Wegner’s Granulomatosis,
Sarcoidosis, etc. )
Enlargements associated
with systemic
diseases/conditions
• Benign Tumors
• Malignant Tumors
Neoplastic Enlargement
(gingival Tumors)
False Enlargement
MODIFIEDCLASSIFICATION
According to etiology
SHAFER’S CLASSIFICATION
11
Inflammatory gingival
hyperplasia
Non inflammatory (fibrous)
gingival hyperplasia
Combination of inflammatory
and fibrous hyperplasia
Shafer WG, Hine M, Levy B. Shafer’s textbook of oral pathology. Elsevier. New Delhi. 5th ed, 2006.
12
BASED ON DISTRIBUTION
Localized: Limited to the
gingiva adjacent to single or
group of teeth
Generalized: Involving gingiva
throughout the mouth
BASED ON LOCATION
Marginal: Confined to marginal
gingiva
Papillary: Confined to interdental
papilla
Diffuse: Involving the marginal,
attached gingiva and papillae
Discrete : An isolated sessile or
pedunculated, tumour like
enlargement
13
INDICES FOR GINGIVAL
ENLARGEMENT
• Kimbal et al, 1939
• Harris & Ewall, 1942
• Robinson et al, 1945
• Babcock and Nelson, 1964
• Angelopoulos & Goaz et al, 1972
• Conrad et al, 1974
• Barak et al, 1985
• Seymour et al, 1985
• Daley et al, 1986
• Friskopp & Klintman et al, 1986
• Mc Gaw index, 1987
• Kitaneara et al, 1990
• Miller and Damm index, 1992
• King et al, 1993
• Bokenkamp et al, 1994
• Miranda et al, 1998
• New index for DIGO (Ingles et
al), 1999
• Modified Harris & Ewait index,
(Prasad et al, 2002)
VARIOUS INDICES USED TO MEASURE GINGIVAL
ENLARGEMENT
14
BASED ON CLINICAL APPEARANCE
1. Babcock and Nelson, 1964
GRADING OF GINGIVAL ENLARGEMENT
15
Mild No gingival enlargement or a minimal
enlargement.
Moderate Slight but definitive gingival enlargement,
not interfering with function.
Severe Gingival enlargement interfering with the
function.
2. Angelopolus & Goaz –1972
Nery et al (1995) modified by adding interproximal area.
16
Grade 0 No hyperplasia
Grade 1 Hyperplasia covering cervical 3rd of anatomic
crown
Grade 2 Hyperplastic gingiva extending the middle 3rd
of anatomic crown of teeth
Grade 3 Hyperplastic gingiva covering > 2/3rd of
crown of anterior tooth.
17
Grade 0 No signs of inflammation
Grade 1 GE confined to interdental papilla
Grade 2 Enlargement involves papilla &marginal gingiva.
Grade 3 Enlargement covers three quarters or more of crown.
Grade 0 No signs of gingival enlargement.
Grade I Enlargement confined to interdental papilla.
Grade II Enlargement involves papilla and marginal gingiva
Grade III Enlargement covers three quarter or more of the crown
3. Mc Gaw et al (1987)
4. Bokenkamp et al, 1994
BASED ON HISTOPATHOLOGICAL EXAMINATION
Barak et al (1985)
18
Grade 1 Normal width of epithelium - 0.30 to 0.50 mm
Grade 2 Slight hyperplasia - 0.50 to 1.5 mm
Grade 3 moderate hyperplasia - 1.50 to 3.0 mm
Grade 4 severe hyperplasia - 3 to 4 mm
BASED ON ASSESSMENT OF PLASTER STUDY
CASTS
Seymour et al –1985
Included both gingival thickening and encroachment of gingival
tissues on the adjacent crowns.
19
Grade 0 Normal
Grade 1 Thickening from normal upto 2mm
Grade 2 Thickening >2mm
Criteria for assessing gingival thickness in a labio-lingual direction for a
gingival unit.
Criteria for assessing gingival encroachment on adjacent tooth surfaces for a
gingival unit. (MGL = Mucogingival line).
BASED ON PHOTOGRAPHIC ANALYSIS
Ellis & Seymour, 1993
20
0 No encroachment of interdental papilla onto tooth surface.
1 Mild encroachment of interdental papilla, producing a blunted
appearance to papilla tip.
2 Moderate encroachment, involving lateral spread of papilla across buccal
tooth surface of less than one quarter tooth width.
3 Marked encroachment of papilla, i.e., more than 1/4 tooth width. Loss of
normal papilla form.
INDICES FOR DRUG INDUCED
GINGIVAL ENLARGEMENT
21
0 No overgrowth
1 Early changes detectable, without encroachment on the tooth
2 Moderate changes, with increased enlargement of the interdental
papillae and slight encroachment of the gingival tissues onto the
tooth surfaces
3 Marked changes with obvious encroachment of the gingival
tissues onto the tooth surfaces.
Grade 0
Grade 1
NEW CLINICAL INDEX FOR DRUG INDUCED
GINGIVAL OVERGROWTH
22
1 No overgrowth; firm adaptation of the attached gingiva to the underlying
alveolar bone.
2 There is slight stippling; there is no granular appearance or a slightly granular
appearance.
3 A knife-edged papilla is present toward the occlusal surface.
4 There is no increase in density or size of the gingiva.
1 Early overgrowth, as evidenced by an increase in density of the gingiva
with marked stippling and granular appearance.
2 The tip of the papilla is rounded.
3 The probing depth is less than or equal to 3 mm.
Grade 2
Grade 3
23
1 Moderate overgrowth, manifested by an increase in the size of the papilla and/or
rolled gingival margins.
2 The contour of the gingival margin is still concave or straight.
3 Gingival enlargement has a bucco-lingual dimension of up to 2 mm, measured
from the tip of the papilla outward.
4 The probing depth is equal to or less than 6 mm.
5 The papilla is somewhat retractable.
1 Marked overgrowth, represented by encroachment of the gingiva onto the
clinical crown.
2 The contour of the gingival margin is convex rather than concave.
3 Gingival enlargement has a bucco-lingual dimension of approximately 3 mm or
more, measured from the tip of the papilla outward.
4 The probing depth is greater than 6 mm.
5 The papilla is clearly retractable.
Grade 4
24
1 Severe overgrowth, characterized by a profound thickening of the gingiva
2 A large percentage of the clinical crown is covered.
3 Same as for grade 3: The papilla is retractable, the probing depth is greater
than 6 mm, and the buccolingually dimension is approximately 3 mm.
DRUGS ASSOCIATED WITH GINGIVAL
ENLARGEMENT
25
Anticonvulsants
Miscellaneous
Calcium channel
blockers
Immunosuppressants
PREVALENCE RATE
26
Phenytoin
50%Cyclosporine
30%
Nifedipine
20%
Drugs modify the inflammatory and immunologic
responses of the host to plaque
Goldman et al
Clinically & histologically
gingival overgrowth induced by different drugs, are
virtually indistinguishable.
Wysocki et al 1983, Tyldesley & Rotter 1984
ANTICONVULSANTS
27
HYDANTOINS SUCCINIMIDES VALPROIC ACID
Ethotoin (Peganone®) Ethosuximide (Zarontin®) Depakene (Depakote®)
Mephenytoin (Mesantoin®) Methsuximide (Celontin®)
Phenytoin (Dilantin®) Phensuximide (Milontin®)
Kimball 1939 - First to report gingival enlargement with chronic usage of
Phenytoin.
Children & Adolescents
Adults
Anterior region
Posterior Region
28
Uses Threshold
plasma
concentration
Incidence Active
metabolite
Progression
Epilepsy –
generalized
tonic-clonic
seizures, partial
seizures.
10-20µg/ml (Rees
et al, 1993)
0 - 84.5%,
Average 50%
(Angelopoulo
s et al)
5-
parahydroxyp
henyl-5-
phenylhydant
oin
Onset – after
one month of
use.
Trigeminal &
related
neuralgias
↑ prevalence
in children
(Dahllof &
Modeer)
Maximum
severity
reached: 12-18
months
Cardiac
arrhythmias
Decreased rate
observed: in the
second year
Adverse drug effects
1. Nausea, Vomitting, Epigastric pain & anorexia.
2. Nystgmus, Diplopia, Ataxia.
3. Gingival hyperplasia (common in children on prolonged use).
4. Peripheral neuropathy.
5. Endocrine – i) Hirsuitism, acne, coarsening of facial features
ii) Hyperglycemia,
iii)Osteomalacia, hypocalcaemia
6. Hypersensitivity reactions
7. Megaloblastic Anaemia
8. Teratogenicity
PHENYTOIN
29
Immunosuppressants
Cyclosporin A
Tacrolimus
Cyclosporin – A
First isolated in Switzerland – 1970, Jean Borel
First case reported by - Rateitschak Pluss,1983
Suppress some humoral immunity (B lymphocytes)
and to a much greater extent, cell-mediated
immunity (T lymphocytes) such as allograft
rejection, delayed hypersensitivity.
Inhibits IL-2 synthesis and release.
30
IMMUNOSUPPRESSANTS
Uses Threshold
plasma
concentration
Incidence Active
metabolite
Progression
Immunosuppressant in
transplant rejection
(kidney, heart, liver
transplant)
> 400ng/ml 25% of renal
transplant
cases
OL-17 Progressive
enlargement
occurs over
several months
Treatment of
rheumatoid arthritis,
psoriasis
38% of
Cardiac
transplants
Reaches peak
after one year of
treatment
Severe atopic
dermatitis, chronic
autoimmune urticaria
37% of Liver
transplants
Graft-versus Host
reaction
Adverse drug effects
1. Nephrotoxicity
2. Hepatotoxicity
3. Anorexia
4. Gum hypertrophy
5. Increased susceptibility to infections
Friskopp & Klintmalm (1986)- Enlargement restricted to keratinized gingiva but can
extend coronally. Absent in edentulous areas.
CALCIUM CHANNEL BLOCKERS
31
Dihydropyridine
derivatives
Benzothiazine derivatives Phenylalkylamine
derivatives
Amlodipine
(Lotrel®, Norvasc ®)
Diltiazem
(Cardizem®, Dilacor®,
Tiazac®)
Verapamil HCL
(Calan®, Isoptin®,
Verelan®)
Felodipine (Plendil®)
Nifedipine
(Adalat®, Procardia ®)
Nimodipine (Nimotop®)
Lederman et al, 1984 - First to report gingival enlargement with
chronic usage of Nifedipine
32
Uses Pulmonary Hypertension Raynaud’s phenomena
Threshold plasma
concentration
800ng/ml Resulted in gingival
overgrowth (rat model)
Nishikawa et al. 1995
Incidence 15% - 84% Avg: 42.5%
Severity Increases the risk of
periodontal destruction
in patients with diabetes
mellitus type 2
Does not appear to affect
edentulous areas,
Nifedipine induced gingival
enlargement is seen around
implants.
(Silverstein et al 1995)
Adverse drug effects
1. Cardiac depression
2. Facial flushing
3. Dizziness
4. Headache
5. Edema
6. Gingival enlargement
33
MISCELLANEOUS
Prednisone
Prednisolone
Valsartan
Atenolol
Paracetamol
Lysine acetylsalicylate
Acebutalol
Metoprolol
Isosorbide dinitrate
Trinitrine
Spironolactone
Allopurinol
Oral contraceptives
Containing :
Ethinylestradiol
Levonorgestrel
Desogestrel
34
CLINICAL FEATURES OF DRUG
INDUCED GINGIVAL ENLARGEMENT
CLINICAL FEATURES OF DRUG INDUCED
GINGIVAL ENLARGEMENT
• Growth starts as:
o A painless beadlike enlargement of the interdental papilla
o Extends to facial & lingual gingival margins.
• On progression:
o Marginal & papillary enlargements unite
o Develop into massive tissue fold covering large part of crown
o Interfere with occlusion
• When uncomplicated by inflammation:
o Lesion is mulberry shaped
o Firm and resilient
o Pale pink
o Minutely lobulated surface
o No tendency to bleed
35
• Enlargement characteristically appears to:
o Project from beneath the gingival margin
o From which it is separated by a linear groove.
• Enlargement is usually generalized
• More severe in maxillary & mandibular anterior regions.
• Occurs in areas in which teeth are present & not in edentulous spaces.
• Plaque control becomes difficult due to the enlargement
Resulting
Secondary inflammatory process
(Further complicates the gingival overgrowth caused by the drug)
36
Resultant enlargement
Increase in size caused by the drug + plaque induced inflammation.
• Drug-induced enlargement may occur in mouths:
o With little or no plaque
o May be absent in mouths with abundant deposits.
• Enlargement is:
o Chronic
o Slowly increases in size.
o When surgically removed, it recurs.
o Spontaneous disappearance occurs within a few months after
discontinuation of the drug.
37
HISTOPATHOLOGY
• Pronounced hyperplasia of the connective tissue & epithelium.
• Acanthosis of the epithelium.
• Elongated rete pegs extending deep into the connective tissue.
• Densely arranged collagen bundles.
• Increase in the number of fibroblasts & new blood vessels.
• Abundance of amorphous ground substance.
Mariani et al
38
39
CLINICAL AND HISTOPATHOLOGIC
FEATURES OF VARIOUS DRUGS
DRUGS CLINICAL FEATURES HISTOPATHOLOGY
PHENYTOIN • Granular or pebbly surface of affected
tissues enlarged papillae extending facially
&/or lingually.
• Formation of pseudoclefts due to
confluence of enlarged papillae
(Hallmon & Rossmann)
• Florid overgrowth of affected papillae.
• Rare cases - observed in edentulous
patients & beneath pontics of FPDs
(McCord J, Sloan P, 1992)
• Fibroblast to collagen
ratio equal to that of
normal gingiva from
normal individuals.
Florid overgrowth of affected papillae and presence of pseudoclefts
resulting from overlapping of adjacent marginal gingiva and
papillary confluence after long term Phenytoin use.
40
DRUGS CLINICAL FEATURES HISTOPATHOLOGY
CYCLOSPORIN A
• Affects children more frequently
• Enlarged gingival tissues are soft
• Extremely fragile
• Red or bluish red
• Bleed easily upon probing.
• Restricted to keratinized gingiva only, so
no interference with occlusion,
mastication or speech.
(Friskopp and Klintmalm, 1996)
• More hyperemic than phenytoin
induced enlargement.
(Seymour & Jacobs, 1992)
• Highly vascular
connective tissue with
foci of chronic
inflammatory cells,
particularly plasma
cells .
NIFEDIPINE
• Enlarged interdental papilla.
• Lobulated /nodular morphology.
• 10 fold increase in
epithelial width.
• Increase capillary
vascularity
• Slight perivascular
inflammation.
CYCLOSPORINE INDUCED GINGIVAL OVERGROWTH
HISTOPATHOLOGY OF DRUG–INDUCEDGINGIVALENLARGEMENT
PHENYTOIN
NIFEDIPINE
CYCLOSPORIN A
Fibroblast to collagen ratio in mature
lesion is equal to that of normal gingiva
from normal individuals
Highly vascular connective tissue with
foci of chronic inflammatory cells,
particularly plasma cells.
• Ten fold increase in epithelial width.
• Increased capillary vascularity and slight
perivascular inflammation.
41
42
PATHOGENESIS OF DRUG
INDUCED GINGIVAL
ENLARGEMENT
PATHOGENESIS OF DIGO
43
Pathogenesis
Increased collagen
synthesis Decreased collagen
degradation
- Extracellular pathway
- Intracellular pathway
Combination
DRUG METABOLITES (Phenytoin, Nifedipine, Cyclosporin)
Increased collagen production
Increased extracellular matrix synthesis
T- lymphocytes
TH2 response
IL-13, 1L4
Macrophages
TGF-β
CTGF
FGF-2
PDGF
44
INCREASED COLLAGEN SYNTHESIS
FIBROBLASTS
Proliferation of highly active fibroblasts
45
DECREASED COLLAGEN DEGRADATION
Drugs associated with gingival enlargement
(Anticonvulsants, Immunosuppressants, CCB, others)
Disturbance in calcium homeostasis
Decreased influx of Ca2+ into fibroblast
Decreased uptake of Ca2+ dependant folic
acid by fibroblasts
Decreased production of active collagenase
Increased expression of TIMP
Decreased MMP 1, 2 & 3
mediated collagen degradation
Waxman et al, 1970
Long term phenytoin therapy
Low serum level of folic acid
Drug metabolite reduces the absorption from GIT
Blocks the transport across intestinal epithelium
Decreased folate reductase
Impaired maturation of epithelium
Connective tissue susceptible to inflammation
46
Decreased collagen phagocytosis
Phenytoin induced
Reduced α2β1 Integrin expression on
fibroblasts
Decreased adhesion of Type 1 Collagen
with Fibroblast
Decreased Endocytosis
Decreased phagocytosis of Type 1 collagen
Fibroblast Apoptosis
Phenytoin induced
Decreased Fibroblast apoptosis
Contribute to fibrosis
Increased number of fibroblasts
Extracellular matrix accumulation
Kantarci P A, 2007
47
INTRACELLULAR PATHWAY
α 2β1 receptors
Receptors UPARAP/ENDO 180 – One of the main
receptors responsible for collagen phagocytosis.
Not enough evidence to substantiate the role of this
receptor.
Joice et al: Phenytoin Induced Gingival overgrowth: A review of the cellular, molecular and inflammatory
features 10.5402/2011/497850
Modification of immune
cells by drug metabolites
Imbalance in production of
cytokines and other mediators
Increased TGFβ1, FGF-2
and others
TGFβ1
Increases synthesis and
deposit of collagen.
Regulation of TIMP.
Reduction of collagen
phagocytosis.
Myofibroblasts are
associated with
later stages of
tissue turnover.
48
49
RISK FACTORS FOR DRUG
INDUCED GINGIVAL
ENLARGEMENT
RISK FACTORS FOR DRUG INDUCED GINGIVAL
ENLARGEMENT
RISK FACTORS
1. Age
2. Genetic factors
3. Pharmacokinetic variables
4. Alterations in the gingival connective tissue
5. Drug induced action on growth factors.
UNIFYING HYPOTHESIS
Vogel et al discussed first the possible
mechanism of pathogenesis that
grouped several current hypothesis
together.
DISSIMILAR DRUGS - SIMILAR
EFFECTS
Action on Ca2+ & Na+ influx
Link between dissimilar drugs
causing gingival enlargement
50
51
AGE
Fibroblasts in areas of Inflamed gingival tissues
Androgen (Testosterone)
5 α- Dihydrotestosterone (5α DHT)
Biologically active
Stimulation of biosynthetic activity in subpopulation of fibroblasts
Increased collagen production
Children/Adolescent
Increased production of
androgen (testosterone)
Sooriyamoorthy M, Gower D, Eley BM. Androgen metabolism in gingival hyperplasia
induced by Nifedipine and Cyclosporin. JOP. 1990;25:25-30
52
GENETIC PREDISPOSITION
PHENYTOIN/CYCLOSPORINE/CCB
Altered metabolism of drug
Threshold concentration of drug/metabolite
Disturbance in calcium homeostasis
Decreased Folate Reductase Gingival fibroblasts are activated
Decreased collagen breakdown
Cytochrome P450
Genotype C807
53
PHARMACOKINETIC VARIABLES
Systemic administration of drug
Local sequestration
Increased concentration
in saliva/GCF
Threshold concentration
Altered fibroblast activity
Concomitant Medication:
Higher Incidence, Severity
& Recurrence rate
Phenytoin + Cyclosporin
Bokenkamp 1994
Margiotta 1996
Prednisolone & Azathioprine -
Combined
immunosuppressant action
with Phenytoin, Cyclosporin &
Calcium channel blockers
Degree of salivary
Phenytoin & gingival
overgrowth
Babcock & Nelson1964
Cyclosporin concentration
in stimulated saliva
& extent of gingival
overgrowth
Mc Gaw et al 1987
Hefti et al 1994
Assumption:
Serum concentration of
active drug > gingival
enlargement to occur.
Threshold differs between:
o Individuals
o Drug to drug
Seymour,1988, 2000
Daley et al1986
Patients exhibiting gingival
overgrowth
Nifedipine & Amlodipine
Conclusions:
1. Can be detected in GCF
2. Significant sequestration of drug
Ellis et al. 1992
Seymour et al. 1994
Direct relationship
54
ALTERATION IN CONNECTIVE TISSUE METABOLISM
HOMEOSTATIC BALANCE
Collagen production Collagen degradation
ALTERED METABOLISM
Fibroblast heterogeneity
Hyperactivity Increased TIMP (Tipton et al, 1991)
Decreased/abnormal Collagenase
Increased collagen production
(Goultchin & Shoskan 1980)
Decreased collagen breakdown
Acanthosis & accumulation of non collagenous extracellular
substances
In addition deficiency of Cathepsin B and L together with
increased levels of Hexose amine, Hyaluronic acid and total
protein content.
55
.
PHENYTOIN
Responders: Up-regulation of EGF
receptor metabolism
Non responders: Down-regulation of
EGF receptor metabolism
Modeer et al 1990
d PDGF secretion from
macrophages
Dill et al. 1993
Abnormal response to plaque
induced inflammatory changes
DRUG-INDUCEDACTIONON GROWTH
FACTORS
56
MANAGEMENT OF GINGIVAL
ENLARGEMENT
MANAGEMENT OF GINGIVAL ENLARGEMENT
57
NON SURGICAL
1. Scaling and Root planing
2. Drug Substitution
3. Antimicrobials
4. Supplements
SURGICAL
1. Gingivoplasty
2. Gingivectomy
3. Periodontal flap surgery
58
Mouth wash
Chlorhexidine Gluconate – 0.2 %
Metronidazole
Usage is controversial
Increases drug metabolites
of Cyclosporin in blood.
Adverse drug effects of
Cyclosporin Seen
Azithromycin
Mechanism of Action:
 High intracellular accumulation (Azithromycin
metabolites):
o Endogenous defense cells
o Tissues affected by inflammatory changes
 Increase phagocytosis of collagen fibres
Counter acts
Decreasing accumulation of extracellular matrix
ANTIBIOTICS
Dannewitz B, Proliferation of the gingiva: etiology, risk factors and treatment modalities for gingival
enlargement. Perio 2007;4(2):83-92
59
SUBSTITUTE FOR
NIFEDIPINE
SUBSTITUTE FOR
CYCLOSPORIN A
SUBSTITUTE FOR
PHENYTOIN
Isradipine
20 mg BD
Tacrolimus
(0.15 - 0.20/kg/d)
Phenobarbital
60 mg TDS
ACE Inhibitors
- Captopril
12.5 - 50 mg BD
- Enalapril
(2.5 - 20 mg OD)
Rapamycin Primidone
100 mg TDS
Carbamazepine
200 – 400 mg TDS
Valproic acid
200 – 500 mg TDS
60
No sufficient data exists to indicate folic acid therapy is
beneficial in Phenytoin induced Gingival enlargement
PHENYTOIN INDUCED GINGIVAL
ENLARGEMENT
Therapeutic benefits
Inove & Harrison, Prasad et al
No therapeutic
benefits
Brown et al, Majota et al
Folic acid therapy
GINGIVECTOMY
ELECTROSURGERY
LASER
CHEMOSURGERY
CONVENTIONAL
61
62
1. Text book of Periodontology by Carranza FA. 10th edition 2007.
2. Textbook of Periodontics, Medicine, surgery and Implants by Rose,
Mealey, Genco. 2004.
3. Paulo M, Camargo, Philip R, Melnick, Flavia M, Pirih, Takei. Treatment of
drug-induced gingival enlargement: aesthetic and functional
considerations. Periodontology 2000, Vol. 27, 2001, 131–138.
4. William W, Hallmon, Jeffrey A, Rossmann. The role of drugs in the
pathogenesis of gingival overgrowth: A collective review of current
concepts. Periodontology 2000, Vol. 21, 1999, 176-196.
5. Michelle L, Moffitt, David E, Bencivenni, Robert E Cohen. Drug-Induced
Gingival Enlargement: An Overview. Compend; CDE 2; 2013, 34: 5.
63
6. Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug-induced
gingival hyperplasia. On the mechanism of DIGH. Oral Pathol Med. 1991;
20:201-9.
7. Nyska A, M. Shemesh, H Tal, Dayan D. Gingival Hyperplasia Induced by
Calcium Channel Blockers: Mode of Action. Medical Hypothesis. 1994;
43:115-118.
8. Christina Popova, Antoaneta Mlachkova. Surgical approach to drug -
induced
9. gingival enlargement in renal transplant patients: Case report. J of IMAB,
2007, vol. 13, book 2.
10. Arnold D Steinberg. Clinical management of phenytoin-induced gingival
overgrowth in handicapped children. Pediatric dentistry. Volume 3,
Special Issue.
11. Chae HJ, Ha MS, Yun DH, Chung HT. Mechanism of Cyclosporine-induced
Overgrowth in Gingiva. J Dent Res85(6):515-519, 2006.
64
C
A
S
E
1
C
A
S
E
2
65

More Related Content

What's hot

Bone loss and patterns of bone destruction
Bone loss and patterns of bone destructionBone loss and patterns of bone destruction
Bone loss and patterns of bone destructionJ.Rahul Raghavender
 
Gingival recession classifications
Gingival recession classifications Gingival recession classifications
Gingival recession classifications Achi Joshi
 
Resective osseous surgery
Resective osseous surgeryResective osseous surgery
Resective osseous surgeryShilpa Shiv
 
Trauma from occlusion
Trauma from occlusionTrauma from occlusion
Trauma from occlusionAnkita Dadwal
 
Aggressive periodontitis
Aggressive periodontitisAggressive periodontitis
Aggressive periodontitisBinaya Subedi
 
"GUIDED TISSUE REGENERATION"
"GUIDED TISSUE REGENERATION""GUIDED TISSUE REGENERATION"
"GUIDED TISSUE REGENERATION"Dr.Pradnya Wagh
 
Furcation involvement and management
Furcation involvement and managementFurcation involvement and management
Furcation involvement and managementAishwarya Hajare
 
Furcation involvement
Furcation involvementFurcation involvement
Furcation involvementneeti shinde
 
advanced diagnostic aids in periodontics
advanced diagnostic aids in periodonticsadvanced diagnostic aids in periodontics
advanced diagnostic aids in periodonticsMehul Shinde
 
Mucogingival surgery in periodontics
Mucogingival surgery in periodonticsMucogingival surgery in periodontics
Mucogingival surgery in periodonticsBinaya Subedi
 
Pathologic migration
Pathologic migrationPathologic migration
Pathologic migrationsruthi K
 
Chemical Plaque Control
 Chemical Plaque Control Chemical Plaque Control
Chemical Plaque ControlMehul Shinde
 

What's hot (20)

Bone loss and patterns of bone destruction
Bone loss and patterns of bone destructionBone loss and patterns of bone destruction
Bone loss and patterns of bone destruction
 
Gingival recession classifications
Gingival recession classifications Gingival recession classifications
Gingival recession classifications
 
Periodontal Flap
Periodontal FlapPeriodontal Flap
Periodontal Flap
 
Resective osseous surgery
Resective osseous surgeryResective osseous surgery
Resective osseous surgery
 
Trauma from occlusion
Trauma from occlusionTrauma from occlusion
Trauma from occlusion
 
Gingival crevicular fluid
Gingival crevicular fluidGingival crevicular fluid
Gingival crevicular fluid
 
Aggressive periodontitis
Aggressive periodontitisAggressive periodontitis
Aggressive periodontitis
 
"GUIDED TISSUE REGENERATION"
"GUIDED TISSUE REGENERATION""GUIDED TISSUE REGENERATION"
"GUIDED TISSUE REGENERATION"
 
Host modulation
Host modulationHost modulation
Host modulation
 
Furcation involvement and management
Furcation involvement and managementFurcation involvement and management
Furcation involvement and management
 
Furcation involvement
Furcation involvementFurcation involvement
Furcation involvement
 
Periodontal flap
Periodontal flapPeriodontal flap
Periodontal flap
 
Junctional epithelium
Junctional epitheliumJunctional epithelium
Junctional epithelium
 
ROOT COVERAGE PROCEDURES
ROOT COVERAGE PROCEDURESROOT COVERAGE PROCEDURES
ROOT COVERAGE PROCEDURES
 
advanced diagnostic aids in periodontics
advanced diagnostic aids in periodonticsadvanced diagnostic aids in periodontics
advanced diagnostic aids in periodontics
 
Mucogingival surgery in periodontics
Mucogingival surgery in periodonticsMucogingival surgery in periodontics
Mucogingival surgery in periodontics
 
Pathologic migration
Pathologic migrationPathologic migration
Pathologic migration
 
Chemical Plaque Control
 Chemical Plaque Control Chemical Plaque Control
Chemical Plaque Control
 
Periodontal plastic surgery
Periodontal plastic surgeryPeriodontal plastic surgery
Periodontal plastic surgery
 
ANUG
ANUGANUG
ANUG
 

Similar to DRUG INDUCED GINGIVAL ENLARGMENT (DIGO)

Gingival enlargement
Gingival enlargementGingival enlargement
Gingival enlargementzebazareen
 
Gingival_enlargement_ppt.pptx
Gingival_enlargement_ppt.pptxGingival_enlargement_ppt.pptx
Gingival_enlargement_ppt.pptxmalti19
 
GINGIVAL_ENLARGEMENT[1].pptx
GINGIVAL_ENLARGEMENT[1].pptxGINGIVAL_ENLARGEMENT[1].pptx
GINGIVAL_ENLARGEMENT[1].pptxveena621629
 
Gingivalenlargment HOD SIR.pptx
Gingivalenlargment HOD SIR.pptxGingivalenlargment HOD SIR.pptx
Gingivalenlargment HOD SIR.pptxDentalYoutube
 
Gingival enlargement
Gingival enlargementGingival enlargement
Gingival enlargementyaskodental
 
Gingival enlrgment
Gingival enlrgmentGingival enlrgment
Gingival enlrgmentImran Bhatt
 
INFLAMMATORY GINGIVAL ENLARGEMENT.pptx
INFLAMMATORY GINGIVAL ENLARGEMENT.pptxINFLAMMATORY GINGIVAL ENLARGEMENT.pptx
INFLAMMATORY GINGIVAL ENLARGEMENT.pptxSaiLakshmi128
 
GINGIVAL ENLARGEMENT: PART-1 AND PART-2
GINGIVAL ENLARGEMENT: PART-1 AND PART-2GINGIVAL ENLARGEMENT: PART-1 AND PART-2
GINGIVAL ENLARGEMENT: PART-1 AND PART-2Dr. Shashi Kiran
 
Gingival enlargement
Gingival enlargementGingival enlargement
Gingival enlargementRiya Shah
 
Gingival Enlargement.ppt
Gingival Enlargement.pptGingival Enlargement.ppt
Gingival Enlargement.pptpayampayamy1
 
Gingival Enlargement.ppt
Gingival Enlargement.pptGingival Enlargement.ppt
Gingival Enlargement.pptpayampayamy1
 
Gingival Enlargementdental periodontal.pptx
Gingival Enlargementdental periodontal.pptxGingival Enlargementdental periodontal.pptx
Gingival Enlargementdental periodontal.pptxMohamedYElZahar
 
Gingival inflammation & clinical features of gingivitis
Gingival inflammation & clinical features of gingivitisGingival inflammation & clinical features of gingivitis
Gingival inflammation & clinical features of gingivitisKiranpreet Kaur Grewal
 
Gingival and Periondantal diseases in children
 Gingival and Periondantal diseases in children Gingival and Periondantal diseases in children
Gingival and Periondantal diseases in childrenDr.Shagun Agarwal
 
Pedodontics iii lecture 07
Pedodontics iii lecture 07Pedodontics iii lecture 07
Pedodontics iii lecture 07Lama K Banna
 
Gingival Enlargement
Gingival EnlargementGingival Enlargement
Gingival EnlargementMaryam Arbab
 

Similar to DRUG INDUCED GINGIVAL ENLARGMENT (DIGO) (20)

Gingival enlargement
Gingival enlargementGingival enlargement
Gingival enlargement
 
Gingival_enlargement_ppt.pptx
Gingival_enlargement_ppt.pptxGingival_enlargement_ppt.pptx
Gingival_enlargement_ppt.pptx
 
GINGIVAL_ENLARGEMENT[1].pptx
GINGIVAL_ENLARGEMENT[1].pptxGINGIVAL_ENLARGEMENT[1].pptx
GINGIVAL_ENLARGEMENT[1].pptx
 
Gingivalenlargment HOD SIR.pptx
Gingivalenlargment HOD SIR.pptxGingivalenlargment HOD SIR.pptx
Gingivalenlargment HOD SIR.pptx
 
Gingival enlargement
Gingival enlargementGingival enlargement
Gingival enlargement
 
Gingival enlargement
Gingival  enlargementGingival  enlargement
Gingival enlargement
 
Gingival enlrgment
Gingival enlrgmentGingival enlrgment
Gingival enlrgment
 
INFLAMMATORY GINGIVAL ENLARGEMENT.pptx
INFLAMMATORY GINGIVAL ENLARGEMENT.pptxINFLAMMATORY GINGIVAL ENLARGEMENT.pptx
INFLAMMATORY GINGIVAL ENLARGEMENT.pptx
 
GINGIVAL ENLARGEMENT
GINGIVAL ENLARGEMENTGINGIVAL ENLARGEMENT
GINGIVAL ENLARGEMENT
 
GINGIVAL ENLARGEMENT: PART-1 AND PART-2
GINGIVAL ENLARGEMENT: PART-1 AND PART-2GINGIVAL ENLARGEMENT: PART-1 AND PART-2
GINGIVAL ENLARGEMENT: PART-1 AND PART-2
 
Gingival enlargement
Gingival enlargementGingival enlargement
Gingival enlargement
 
Gingival Enlargement.ppt
Gingival Enlargement.pptGingival Enlargement.ppt
Gingival Enlargement.ppt
 
Gingival Enlargement.ppt
Gingival Enlargement.pptGingival Enlargement.ppt
Gingival Enlargement.ppt
 
Gingival enlargement
Gingival enlargementGingival enlargement
Gingival enlargement
 
Gingival Enlargementdental periodontal.pptx
Gingival Enlargementdental periodontal.pptxGingival Enlargementdental periodontal.pptx
Gingival Enlargementdental periodontal.pptx
 
GINGIVAL ENLARGEMENT+MGMT
GINGIVAL ENLARGEMENT+MGMTGINGIVAL ENLARGEMENT+MGMT
GINGIVAL ENLARGEMENT+MGMT
 
Gingival inflammation & clinical features of gingivitis
Gingival inflammation & clinical features of gingivitisGingival inflammation & clinical features of gingivitis
Gingival inflammation & clinical features of gingivitis
 
Gingival and Periondantal diseases in children
 Gingival and Periondantal diseases in children Gingival and Periondantal diseases in children
Gingival and Periondantal diseases in children
 
Pedodontics iii lecture 07
Pedodontics iii lecture 07Pedodontics iii lecture 07
Pedodontics iii lecture 07
 
Gingival Enlargement
Gingival EnlargementGingival Enlargement
Gingival Enlargement
 

More from Aishwarya Hajare

Lab investigations and interpretations in periodontics
Lab investigations and interpretations in periodonticsLab investigations and interpretations in periodontics
Lab investigations and interpretations in periodonticsAishwarya Hajare
 
Local drug delivery system
Local drug delivery systemLocal drug delivery system
Local drug delivery systemAishwarya Hajare
 
Neutrophil in health and disease
Neutrophil in health and diseaseNeutrophil in health and disease
Neutrophil in health and diseaseAishwarya Hajare
 
Defense mechansism of gingiva
Defense mechansism of gingivaDefense mechansism of gingiva
Defense mechansism of gingivaAishwarya Hajare
 
Microbiology of periodontal diseases
Microbiology of periodontal diseasesMicrobiology of periodontal diseases
Microbiology of periodontal diseasesAishwarya Hajare
 
Aggregatibacter actinomycetemcomitans
Aggregatibacter actinomycetemcomitansAggregatibacter actinomycetemcomitans
Aggregatibacter actinomycetemcomitansAishwarya Hajare
 
Bacterial growth & metabolism
Bacterial growth & metabolism Bacterial growth & metabolism
Bacterial growth & metabolism Aishwarya Hajare
 
Lymphatics of head and neck
Lymphatics of head and neckLymphatics of head and neck
Lymphatics of head and neckAishwarya Hajare
 
Sterilization and disinfection in dentistry
Sterilization and disinfection in dentistrySterilization and disinfection in dentistry
Sterilization and disinfection in dentistryAishwarya Hajare
 
Blood supplyand lymphatic drainage to oral cavity
Blood supplyand lymphatic drainage to oral cavityBlood supplyand lymphatic drainage to oral cavity
Blood supplyand lymphatic drainage to oral cavityAishwarya Hajare
 
Trigeminal nerve and its dental implications
Trigeminal nerve and its dental implicationsTrigeminal nerve and its dental implications
Trigeminal nerve and its dental implicationsAishwarya Hajare
 

More from Aishwarya Hajare (13)

Splinting in Periodontics
Splinting in PeriodonticsSplinting in Periodontics
Splinting in Periodontics
 
PRO AND PREBIOTICS
PRO AND PREBIOTICSPRO AND PREBIOTICS
PRO AND PREBIOTICS
 
Lab investigations and interpretations in periodontics
Lab investigations and interpretations in periodonticsLab investigations and interpretations in periodontics
Lab investigations and interpretations in periodontics
 
Local drug delivery system
Local drug delivery systemLocal drug delivery system
Local drug delivery system
 
Neutrophil in health and disease
Neutrophil in health and diseaseNeutrophil in health and disease
Neutrophil in health and disease
 
Defense mechansism of gingiva
Defense mechansism of gingivaDefense mechansism of gingiva
Defense mechansism of gingiva
 
Microbiology of periodontal diseases
Microbiology of periodontal diseasesMicrobiology of periodontal diseases
Microbiology of periodontal diseases
 
Aggregatibacter actinomycetemcomitans
Aggregatibacter actinomycetemcomitansAggregatibacter actinomycetemcomitans
Aggregatibacter actinomycetemcomitans
 
Bacterial growth & metabolism
Bacterial growth & metabolism Bacterial growth & metabolism
Bacterial growth & metabolism
 
Lymphatics of head and neck
Lymphatics of head and neckLymphatics of head and neck
Lymphatics of head and neck
 
Sterilization and disinfection in dentistry
Sterilization and disinfection in dentistrySterilization and disinfection in dentistry
Sterilization and disinfection in dentistry
 
Blood supplyand lymphatic drainage to oral cavity
Blood supplyand lymphatic drainage to oral cavityBlood supplyand lymphatic drainage to oral cavity
Blood supplyand lymphatic drainage to oral cavity
 
Trigeminal nerve and its dental implications
Trigeminal nerve and its dental implicationsTrigeminal nerve and its dental implications
Trigeminal nerve and its dental implications
 

Recently uploaded

Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedSBL DIGITAL
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKQuick MedTalk
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptxnakera38
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)chahattyagi200
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersSai Sailesh Kumar Goothy
 
CANCER SeminarCancer Overview Type of Cancer.pptx
CANCER SeminarCancer Overview  Type of Cancer.pptxCANCER SeminarCancer Overview  Type of Cancer.pptx
CANCER SeminarCancer Overview Type of Cancer.pptxMrStavanUdayKadam
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhanthesalberry
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxsiddharthroy26587
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......anupamdas2143
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptxPulkitMittal54
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Ahmad Thanin
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsPradnya Wadekar
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptxRajendra Dev Bhatt
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptKavitha Krishnan
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...DUY NGUYEN PHUC
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionZeinabEmad3
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedSBL DIGITAL
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxSizan Thapa
 

Recently uploaded (20)

Derma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech LimitedDerma Pharmaceutical Franchise Company - Solace Biotech Limited
Derma Pharmaceutical Franchise Company - Solace Biotech Limited
 
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALKLaryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
Laryngeal papillomatosis .pdf ENT BY QUICKMEDTALK
 
airway management recorded for S2.pptx
airway management  recorded  for S2.pptxairway management  recorded  for S2.pptx
airway management recorded for S2.pptx
 
Oral disorders .pptx
Oral disorders .pptxOral disorders .pptx
Oral disorders .pptx
 
(IDE)and(IVD),QMS,21 CFR part820 , 801)
(IDE)and(IVD),QMS,21 CFR part820  , 801)(IDE)and(IVD),QMS,21 CFR part820  , 801)
(IDE)and(IVD),QMS,21 CFR part820 , 801)
 
Thyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disordersThyroid hormones- synthesis, secretion, functions and disorders
Thyroid hormones- synthesis, secretion, functions and disorders
 
CANCER SeminarCancer Overview Type of Cancer.pptx
CANCER SeminarCancer Overview  Type of Cancer.pptxCANCER SeminarCancer Overview  Type of Cancer.pptx
CANCER SeminarCancer Overview Type of Cancer.pptx
 
bleeding disorders 1 Dr.Nannika Pradhan
bleeding disorders 1  Dr.Nannika Pradhanbleeding disorders 1  Dr.Nannika Pradhan
bleeding disorders 1 Dr.Nannika Pradhan
 
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptxANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
ANATOMY OF THE CEREBRUM WITH CLINICAL ANATOMY.pptx
 
Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......Human Skeletal System_By Anupam Das......
Human Skeletal System_By Anupam Das......
 
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY  pptxHERPES SIMPLEX VIRUS 12032019 TUESDAY  pptx
HERPES SIMPLEX VIRUS 12032019 TUESDAY pptx
 
Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)Methicillin-resistant Staphylococcus Aureus (MRSA)
Methicillin-resistant Staphylococcus Aureus (MRSA)
 
Neutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractionsNeutraceuticals, Herb-drug & Herb-food inetractions
Neutraceuticals, Herb-drug & Herb-food inetractions
 
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptxCholesterol Biosynthesis  and catabolism for MBBS, Lab. MEd. BDS.pptx
Cholesterol Biosynthesis and catabolism for MBBS, Lab. MEd. BDS.pptx
 
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.pptINTRODUCTION TO THE FORENSIC SCIENCE.ppt
INTRODUCTION TO THE FORENSIC SCIENCE.ppt
 
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...Routine Medicine Laboratory Testing  _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
Routine Medicine Laboratory Testing _ CÁC XÉT NGHIỆM THƯỜNG QUY ÁP DỤNG TRON...
 
Substance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), AddictionSubstance use disorder (drug addict ), Addiction
Substance use disorder (drug addict ), Addiction
 
Ortho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limitedOrtho Products Franchise-solace biotech limited
Ortho Products Franchise-solace biotech limited
 
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
Catalysts for Change in SCLC: Optimizing the Use of Standard Therapies and Ac...
 
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptxNECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
NECROSIS FOR MBBS FIRST YEAR STUDENTS MADE EASY.pptx
 

DRUG INDUCED GINGIVAL ENLARGMENT (DIGO)

  • 2. 1. Introduction 2. Classification of gingival enlargement 3. Indices for gingival enlargement 4. Drugs associated with gingival enlargement o Anticonvulsants o Immunosuppressants o Calcium Channel blockers o Miscellaneous 8. Prevalence of drugs causing gingival enlargement 9. Clinical manifestations and Histopathologic features 10. Pathogenesis of Drug induced gingival enlargement 11. Risk factors for Drug induced gingival enlargement 12. Management 13. References 2
  • 3. Coral PinkScalloped & Knife edged Surface Texture StippledFirm & resilient consistency Size : Cellular + Intercellular + Vasculature Interdental Papilla Anterior – Pyramidal Posterior – Tent shaped Gingiva in health….. 3
  • 4. INCREASE IN SIZE OF GINGIVA INFLAMMATORY TYPE Increased cells Decreased fibers NON - INFLAMMATORY TYPE Increased fibers Decreased cells 4
  • 5. REASONS FOR INCREASE IN SIZE OF GINGIVA Accumulation of: Products of inflammation Increase in: Cellular + fibrous + ground substance 5
  • 6. Various terms used previously Gingival Hyperplasia Gingival Hypertrophy Fibrous gingival Hyperplasia Gingival Overgrowth To denote excessive gingival proliferation secondary to drugs Gingival Enlargement Preferred term 6
  • 7. 7 SEQUELAE OF GINGIVAL OVERGROWTH Aesthetic changes Difficulty in maintaining good oral hygiene Clinical symptoms such as pain Speech disturbances Abnormal tooth movement Dental occlusion problem Enhanced risk of caries & periodontitis Brunnet et al 1996
  • 9. 9 • Acute • Chronic Inflammatory enlargement • Drug induced • Idiopathic Fibrotic enlargement • Fibrotic + InflammatoryCombined enlargement • Conditioned enlargement • Pregnancy • Puberty • Vitamin C Deficiency • Plasma Cell Gingivitis • Non Specific Conditioned Enlargement (Granuloma Pyogenicum) • Systemic diseases causing gingival enlargement • Leukemia • Granulomatous Diseases (Wegner’s Granulomatosis, Sarcoidosis, etc. ) Enlargements associated with systemic diseases/conditions • Benign Tumors • Malignant Tumors Neoplastic Enlargement (gingival Tumors) False Enlargement OLDERCLASSIFICATION According to etiologic factors & pathologic changes
  • 10. 10 • Acute • Chronic Inflammatory enlargement Drug induced enlargement • Conditioned enlargement • Pregnancy • Puberty • Vitamin C Deficiency • Plasma Cell Gingivitis • Non Specific Conditioned Enlargement (Granuloma Pyogenicum) • Systemic diseases causing gingival enlargement • Leukemia • Granulomatous Diseases (Wegner’s Granulomatosis, Sarcoidosis, etc. ) Enlargements associated with systemic diseases/conditions • Benign Tumors • Malignant Tumors Neoplastic Enlargement (gingival Tumors) False Enlargement MODIFIEDCLASSIFICATION According to etiology
  • 11. SHAFER’S CLASSIFICATION 11 Inflammatory gingival hyperplasia Non inflammatory (fibrous) gingival hyperplasia Combination of inflammatory and fibrous hyperplasia Shafer WG, Hine M, Levy B. Shafer’s textbook of oral pathology. Elsevier. New Delhi. 5th ed, 2006.
  • 12. 12 BASED ON DISTRIBUTION Localized: Limited to the gingiva adjacent to single or group of teeth Generalized: Involving gingiva throughout the mouth BASED ON LOCATION Marginal: Confined to marginal gingiva Papillary: Confined to interdental papilla Diffuse: Involving the marginal, attached gingiva and papillae Discrete : An isolated sessile or pedunculated, tumour like enlargement
  • 14. • Kimbal et al, 1939 • Harris & Ewall, 1942 • Robinson et al, 1945 • Babcock and Nelson, 1964 • Angelopoulos & Goaz et al, 1972 • Conrad et al, 1974 • Barak et al, 1985 • Seymour et al, 1985 • Daley et al, 1986 • Friskopp & Klintman et al, 1986 • Mc Gaw index, 1987 • Kitaneara et al, 1990 • Miller and Damm index, 1992 • King et al, 1993 • Bokenkamp et al, 1994 • Miranda et al, 1998 • New index for DIGO (Ingles et al), 1999 • Modified Harris & Ewait index, (Prasad et al, 2002) VARIOUS INDICES USED TO MEASURE GINGIVAL ENLARGEMENT 14
  • 15. BASED ON CLINICAL APPEARANCE 1. Babcock and Nelson, 1964 GRADING OF GINGIVAL ENLARGEMENT 15 Mild No gingival enlargement or a minimal enlargement. Moderate Slight but definitive gingival enlargement, not interfering with function. Severe Gingival enlargement interfering with the function.
  • 16. 2. Angelopolus & Goaz –1972 Nery et al (1995) modified by adding interproximal area. 16 Grade 0 No hyperplasia Grade 1 Hyperplasia covering cervical 3rd of anatomic crown Grade 2 Hyperplastic gingiva extending the middle 3rd of anatomic crown of teeth Grade 3 Hyperplastic gingiva covering > 2/3rd of crown of anterior tooth.
  • 17. 17 Grade 0 No signs of inflammation Grade 1 GE confined to interdental papilla Grade 2 Enlargement involves papilla &marginal gingiva. Grade 3 Enlargement covers three quarters or more of crown. Grade 0 No signs of gingival enlargement. Grade I Enlargement confined to interdental papilla. Grade II Enlargement involves papilla and marginal gingiva Grade III Enlargement covers three quarter or more of the crown 3. Mc Gaw et al (1987) 4. Bokenkamp et al, 1994
  • 18. BASED ON HISTOPATHOLOGICAL EXAMINATION Barak et al (1985) 18 Grade 1 Normal width of epithelium - 0.30 to 0.50 mm Grade 2 Slight hyperplasia - 0.50 to 1.5 mm Grade 3 moderate hyperplasia - 1.50 to 3.0 mm Grade 4 severe hyperplasia - 3 to 4 mm
  • 19. BASED ON ASSESSMENT OF PLASTER STUDY CASTS Seymour et al –1985 Included both gingival thickening and encroachment of gingival tissues on the adjacent crowns. 19 Grade 0 Normal Grade 1 Thickening from normal upto 2mm Grade 2 Thickening >2mm Criteria for assessing gingival thickness in a labio-lingual direction for a gingival unit. Criteria for assessing gingival encroachment on adjacent tooth surfaces for a gingival unit. (MGL = Mucogingival line).
  • 20. BASED ON PHOTOGRAPHIC ANALYSIS Ellis & Seymour, 1993 20 0 No encroachment of interdental papilla onto tooth surface. 1 Mild encroachment of interdental papilla, producing a blunted appearance to papilla tip. 2 Moderate encroachment, involving lateral spread of papilla across buccal tooth surface of less than one quarter tooth width. 3 Marked encroachment of papilla, i.e., more than 1/4 tooth width. Loss of normal papilla form.
  • 21. INDICES FOR DRUG INDUCED GINGIVAL ENLARGEMENT 21 0 No overgrowth 1 Early changes detectable, without encroachment on the tooth 2 Moderate changes, with increased enlargement of the interdental papillae and slight encroachment of the gingival tissues onto the tooth surfaces 3 Marked changes with obvious encroachment of the gingival tissues onto the tooth surfaces.
  • 22. Grade 0 Grade 1 NEW CLINICAL INDEX FOR DRUG INDUCED GINGIVAL OVERGROWTH 22 1 No overgrowth; firm adaptation of the attached gingiva to the underlying alveolar bone. 2 There is slight stippling; there is no granular appearance or a slightly granular appearance. 3 A knife-edged papilla is present toward the occlusal surface. 4 There is no increase in density or size of the gingiva. 1 Early overgrowth, as evidenced by an increase in density of the gingiva with marked stippling and granular appearance. 2 The tip of the papilla is rounded. 3 The probing depth is less than or equal to 3 mm.
  • 23. Grade 2 Grade 3 23 1 Moderate overgrowth, manifested by an increase in the size of the papilla and/or rolled gingival margins. 2 The contour of the gingival margin is still concave or straight. 3 Gingival enlargement has a bucco-lingual dimension of up to 2 mm, measured from the tip of the papilla outward. 4 The probing depth is equal to or less than 6 mm. 5 The papilla is somewhat retractable. 1 Marked overgrowth, represented by encroachment of the gingiva onto the clinical crown. 2 The contour of the gingival margin is convex rather than concave. 3 Gingival enlargement has a bucco-lingual dimension of approximately 3 mm or more, measured from the tip of the papilla outward. 4 The probing depth is greater than 6 mm. 5 The papilla is clearly retractable.
  • 24. Grade 4 24 1 Severe overgrowth, characterized by a profound thickening of the gingiva 2 A large percentage of the clinical crown is covered. 3 Same as for grade 3: The papilla is retractable, the probing depth is greater than 6 mm, and the buccolingually dimension is approximately 3 mm.
  • 25. DRUGS ASSOCIATED WITH GINGIVAL ENLARGEMENT 25 Anticonvulsants Miscellaneous Calcium channel blockers Immunosuppressants
  • 26. PREVALENCE RATE 26 Phenytoin 50%Cyclosporine 30% Nifedipine 20% Drugs modify the inflammatory and immunologic responses of the host to plaque Goldman et al Clinically & histologically gingival overgrowth induced by different drugs, are virtually indistinguishable. Wysocki et al 1983, Tyldesley & Rotter 1984
  • 27. ANTICONVULSANTS 27 HYDANTOINS SUCCINIMIDES VALPROIC ACID Ethotoin (Peganone®) Ethosuximide (Zarontin®) Depakene (Depakote®) Mephenytoin (Mesantoin®) Methsuximide (Celontin®) Phenytoin (Dilantin®) Phensuximide (Milontin®) Kimball 1939 - First to report gingival enlargement with chronic usage of Phenytoin. Children & Adolescents Adults Anterior region Posterior Region
  • 28. 28 Uses Threshold plasma concentration Incidence Active metabolite Progression Epilepsy – generalized tonic-clonic seizures, partial seizures. 10-20µg/ml (Rees et al, 1993) 0 - 84.5%, Average 50% (Angelopoulo s et al) 5- parahydroxyp henyl-5- phenylhydant oin Onset – after one month of use. Trigeminal & related neuralgias ↑ prevalence in children (Dahllof & Modeer) Maximum severity reached: 12-18 months Cardiac arrhythmias Decreased rate observed: in the second year Adverse drug effects 1. Nausea, Vomitting, Epigastric pain & anorexia. 2. Nystgmus, Diplopia, Ataxia. 3. Gingival hyperplasia (common in children on prolonged use). 4. Peripheral neuropathy. 5. Endocrine – i) Hirsuitism, acne, coarsening of facial features ii) Hyperglycemia, iii)Osteomalacia, hypocalcaemia 6. Hypersensitivity reactions 7. Megaloblastic Anaemia 8. Teratogenicity PHENYTOIN
  • 29. 29 Immunosuppressants Cyclosporin A Tacrolimus Cyclosporin – A First isolated in Switzerland – 1970, Jean Borel First case reported by - Rateitschak Pluss,1983 Suppress some humoral immunity (B lymphocytes) and to a much greater extent, cell-mediated immunity (T lymphocytes) such as allograft rejection, delayed hypersensitivity. Inhibits IL-2 synthesis and release.
  • 30. 30 IMMUNOSUPPRESSANTS Uses Threshold plasma concentration Incidence Active metabolite Progression Immunosuppressant in transplant rejection (kidney, heart, liver transplant) > 400ng/ml 25% of renal transplant cases OL-17 Progressive enlargement occurs over several months Treatment of rheumatoid arthritis, psoriasis 38% of Cardiac transplants Reaches peak after one year of treatment Severe atopic dermatitis, chronic autoimmune urticaria 37% of Liver transplants Graft-versus Host reaction Adverse drug effects 1. Nephrotoxicity 2. Hepatotoxicity 3. Anorexia 4. Gum hypertrophy 5. Increased susceptibility to infections Friskopp & Klintmalm (1986)- Enlargement restricted to keratinized gingiva but can extend coronally. Absent in edentulous areas.
  • 31. CALCIUM CHANNEL BLOCKERS 31 Dihydropyridine derivatives Benzothiazine derivatives Phenylalkylamine derivatives Amlodipine (Lotrel®, Norvasc ®) Diltiazem (Cardizem®, Dilacor®, Tiazac®) Verapamil HCL (Calan®, Isoptin®, Verelan®) Felodipine (Plendil®) Nifedipine (Adalat®, Procardia ®) Nimodipine (Nimotop®) Lederman et al, 1984 - First to report gingival enlargement with chronic usage of Nifedipine
  • 32. 32 Uses Pulmonary Hypertension Raynaud’s phenomena Threshold plasma concentration 800ng/ml Resulted in gingival overgrowth (rat model) Nishikawa et al. 1995 Incidence 15% - 84% Avg: 42.5% Severity Increases the risk of periodontal destruction in patients with diabetes mellitus type 2 Does not appear to affect edentulous areas, Nifedipine induced gingival enlargement is seen around implants. (Silverstein et al 1995) Adverse drug effects 1. Cardiac depression 2. Facial flushing 3. Dizziness 4. Headache 5. Edema 6. Gingival enlargement
  • 34. 34 CLINICAL FEATURES OF DRUG INDUCED GINGIVAL ENLARGEMENT
  • 35. CLINICAL FEATURES OF DRUG INDUCED GINGIVAL ENLARGEMENT • Growth starts as: o A painless beadlike enlargement of the interdental papilla o Extends to facial & lingual gingival margins. • On progression: o Marginal & papillary enlargements unite o Develop into massive tissue fold covering large part of crown o Interfere with occlusion • When uncomplicated by inflammation: o Lesion is mulberry shaped o Firm and resilient o Pale pink o Minutely lobulated surface o No tendency to bleed 35
  • 36. • Enlargement characteristically appears to: o Project from beneath the gingival margin o From which it is separated by a linear groove. • Enlargement is usually generalized • More severe in maxillary & mandibular anterior regions. • Occurs in areas in which teeth are present & not in edentulous spaces. • Plaque control becomes difficult due to the enlargement Resulting Secondary inflammatory process (Further complicates the gingival overgrowth caused by the drug) 36
  • 37. Resultant enlargement Increase in size caused by the drug + plaque induced inflammation. • Drug-induced enlargement may occur in mouths: o With little or no plaque o May be absent in mouths with abundant deposits. • Enlargement is: o Chronic o Slowly increases in size. o When surgically removed, it recurs. o Spontaneous disappearance occurs within a few months after discontinuation of the drug. 37
  • 38. HISTOPATHOLOGY • Pronounced hyperplasia of the connective tissue & epithelium. • Acanthosis of the epithelium. • Elongated rete pegs extending deep into the connective tissue. • Densely arranged collagen bundles. • Increase in the number of fibroblasts & new blood vessels. • Abundance of amorphous ground substance. Mariani et al 38
  • 40. DRUGS CLINICAL FEATURES HISTOPATHOLOGY PHENYTOIN • Granular or pebbly surface of affected tissues enlarged papillae extending facially &/or lingually. • Formation of pseudoclefts due to confluence of enlarged papillae (Hallmon & Rossmann) • Florid overgrowth of affected papillae. • Rare cases - observed in edentulous patients & beneath pontics of FPDs (McCord J, Sloan P, 1992) • Fibroblast to collagen ratio equal to that of normal gingiva from normal individuals. Florid overgrowth of affected papillae and presence of pseudoclefts resulting from overlapping of adjacent marginal gingiva and papillary confluence after long term Phenytoin use. 40 DRUGS CLINICAL FEATURES HISTOPATHOLOGY CYCLOSPORIN A • Affects children more frequently • Enlarged gingival tissues are soft • Extremely fragile • Red or bluish red • Bleed easily upon probing. • Restricted to keratinized gingiva only, so no interference with occlusion, mastication or speech. (Friskopp and Klintmalm, 1996) • More hyperemic than phenytoin induced enlargement. (Seymour & Jacobs, 1992) • Highly vascular connective tissue with foci of chronic inflammatory cells, particularly plasma cells . NIFEDIPINE • Enlarged interdental papilla. • Lobulated /nodular morphology. • 10 fold increase in epithelial width. • Increase capillary vascularity • Slight perivascular inflammation. CYCLOSPORINE INDUCED GINGIVAL OVERGROWTH
  • 41. HISTOPATHOLOGY OF DRUG–INDUCEDGINGIVALENLARGEMENT PHENYTOIN NIFEDIPINE CYCLOSPORIN A Fibroblast to collagen ratio in mature lesion is equal to that of normal gingiva from normal individuals Highly vascular connective tissue with foci of chronic inflammatory cells, particularly plasma cells. • Ten fold increase in epithelial width. • Increased capillary vascularity and slight perivascular inflammation. 41
  • 42. 42 PATHOGENESIS OF DRUG INDUCED GINGIVAL ENLARGEMENT
  • 43. PATHOGENESIS OF DIGO 43 Pathogenesis Increased collagen synthesis Decreased collagen degradation - Extracellular pathway - Intracellular pathway Combination
  • 44. DRUG METABOLITES (Phenytoin, Nifedipine, Cyclosporin) Increased collagen production Increased extracellular matrix synthesis T- lymphocytes TH2 response IL-13, 1L4 Macrophages TGF-β CTGF FGF-2 PDGF 44 INCREASED COLLAGEN SYNTHESIS FIBROBLASTS Proliferation of highly active fibroblasts
  • 45. 45 DECREASED COLLAGEN DEGRADATION Drugs associated with gingival enlargement (Anticonvulsants, Immunosuppressants, CCB, others) Disturbance in calcium homeostasis Decreased influx of Ca2+ into fibroblast Decreased uptake of Ca2+ dependant folic acid by fibroblasts Decreased production of active collagenase Increased expression of TIMP Decreased MMP 1, 2 & 3 mediated collagen degradation
  • 46. Waxman et al, 1970 Long term phenytoin therapy Low serum level of folic acid Drug metabolite reduces the absorption from GIT Blocks the transport across intestinal epithelium Decreased folate reductase Impaired maturation of epithelium Connective tissue susceptible to inflammation 46
  • 47. Decreased collagen phagocytosis Phenytoin induced Reduced α2β1 Integrin expression on fibroblasts Decreased adhesion of Type 1 Collagen with Fibroblast Decreased Endocytosis Decreased phagocytosis of Type 1 collagen Fibroblast Apoptosis Phenytoin induced Decreased Fibroblast apoptosis Contribute to fibrosis Increased number of fibroblasts Extracellular matrix accumulation Kantarci P A, 2007 47 INTRACELLULAR PATHWAY α 2β1 receptors Receptors UPARAP/ENDO 180 – One of the main receptors responsible for collagen phagocytosis. Not enough evidence to substantiate the role of this receptor.
  • 48. Joice et al: Phenytoin Induced Gingival overgrowth: A review of the cellular, molecular and inflammatory features 10.5402/2011/497850 Modification of immune cells by drug metabolites Imbalance in production of cytokines and other mediators Increased TGFβ1, FGF-2 and others TGFβ1 Increases synthesis and deposit of collagen. Regulation of TIMP. Reduction of collagen phagocytosis. Myofibroblasts are associated with later stages of tissue turnover. 48
  • 49. 49 RISK FACTORS FOR DRUG INDUCED GINGIVAL ENLARGEMENT
  • 50. RISK FACTORS FOR DRUG INDUCED GINGIVAL ENLARGEMENT RISK FACTORS 1. Age 2. Genetic factors 3. Pharmacokinetic variables 4. Alterations in the gingival connective tissue 5. Drug induced action on growth factors. UNIFYING HYPOTHESIS Vogel et al discussed first the possible mechanism of pathogenesis that grouped several current hypothesis together. DISSIMILAR DRUGS - SIMILAR EFFECTS Action on Ca2+ & Na+ influx Link between dissimilar drugs causing gingival enlargement 50
  • 51. 51 AGE Fibroblasts in areas of Inflamed gingival tissues Androgen (Testosterone) 5 α- Dihydrotestosterone (5α DHT) Biologically active Stimulation of biosynthetic activity in subpopulation of fibroblasts Increased collagen production Children/Adolescent Increased production of androgen (testosterone) Sooriyamoorthy M, Gower D, Eley BM. Androgen metabolism in gingival hyperplasia induced by Nifedipine and Cyclosporin. JOP. 1990;25:25-30
  • 52. 52 GENETIC PREDISPOSITION PHENYTOIN/CYCLOSPORINE/CCB Altered metabolism of drug Threshold concentration of drug/metabolite Disturbance in calcium homeostasis Decreased Folate Reductase Gingival fibroblasts are activated Decreased collagen breakdown Cytochrome P450 Genotype C807
  • 53. 53 PHARMACOKINETIC VARIABLES Systemic administration of drug Local sequestration Increased concentration in saliva/GCF Threshold concentration Altered fibroblast activity Concomitant Medication: Higher Incidence, Severity & Recurrence rate Phenytoin + Cyclosporin Bokenkamp 1994 Margiotta 1996 Prednisolone & Azathioprine - Combined immunosuppressant action with Phenytoin, Cyclosporin & Calcium channel blockers Degree of salivary Phenytoin & gingival overgrowth Babcock & Nelson1964 Cyclosporin concentration in stimulated saliva & extent of gingival overgrowth Mc Gaw et al 1987 Hefti et al 1994 Assumption: Serum concentration of active drug > gingival enlargement to occur. Threshold differs between: o Individuals o Drug to drug Seymour,1988, 2000 Daley et al1986 Patients exhibiting gingival overgrowth Nifedipine & Amlodipine Conclusions: 1. Can be detected in GCF 2. Significant sequestration of drug Ellis et al. 1992 Seymour et al. 1994 Direct relationship
  • 54. 54 ALTERATION IN CONNECTIVE TISSUE METABOLISM HOMEOSTATIC BALANCE Collagen production Collagen degradation ALTERED METABOLISM Fibroblast heterogeneity Hyperactivity Increased TIMP (Tipton et al, 1991) Decreased/abnormal Collagenase Increased collagen production (Goultchin & Shoskan 1980) Decreased collagen breakdown Acanthosis & accumulation of non collagenous extracellular substances In addition deficiency of Cathepsin B and L together with increased levels of Hexose amine, Hyaluronic acid and total protein content.
  • 55. 55 . PHENYTOIN Responders: Up-regulation of EGF receptor metabolism Non responders: Down-regulation of EGF receptor metabolism Modeer et al 1990 d PDGF secretion from macrophages Dill et al. 1993 Abnormal response to plaque induced inflammatory changes DRUG-INDUCEDACTIONON GROWTH FACTORS
  • 57. MANAGEMENT OF GINGIVAL ENLARGEMENT 57 NON SURGICAL 1. Scaling and Root planing 2. Drug Substitution 3. Antimicrobials 4. Supplements SURGICAL 1. Gingivoplasty 2. Gingivectomy 3. Periodontal flap surgery
  • 58. 58 Mouth wash Chlorhexidine Gluconate – 0.2 % Metronidazole Usage is controversial Increases drug metabolites of Cyclosporin in blood. Adverse drug effects of Cyclosporin Seen Azithromycin Mechanism of Action:  High intracellular accumulation (Azithromycin metabolites): o Endogenous defense cells o Tissues affected by inflammatory changes  Increase phagocytosis of collagen fibres Counter acts Decreasing accumulation of extracellular matrix ANTIBIOTICS Dannewitz B, Proliferation of the gingiva: etiology, risk factors and treatment modalities for gingival enlargement. Perio 2007;4(2):83-92
  • 59. 59 SUBSTITUTE FOR NIFEDIPINE SUBSTITUTE FOR CYCLOSPORIN A SUBSTITUTE FOR PHENYTOIN Isradipine 20 mg BD Tacrolimus (0.15 - 0.20/kg/d) Phenobarbital 60 mg TDS ACE Inhibitors - Captopril 12.5 - 50 mg BD - Enalapril (2.5 - 20 mg OD) Rapamycin Primidone 100 mg TDS Carbamazepine 200 – 400 mg TDS Valproic acid 200 – 500 mg TDS
  • 60. 60 No sufficient data exists to indicate folic acid therapy is beneficial in Phenytoin induced Gingival enlargement PHENYTOIN INDUCED GINGIVAL ENLARGEMENT Therapeutic benefits Inove & Harrison, Prasad et al No therapeutic benefits Brown et al, Majota et al Folic acid therapy
  • 62. 62 1. Text book of Periodontology by Carranza FA. 10th edition 2007. 2. Textbook of Periodontics, Medicine, surgery and Implants by Rose, Mealey, Genco. 2004. 3. Paulo M, Camargo, Philip R, Melnick, Flavia M, Pirih, Takei. Treatment of drug-induced gingival enlargement: aesthetic and functional considerations. Periodontology 2000, Vol. 27, 2001, 131–138. 4. William W, Hallmon, Jeffrey A, Rossmann. The role of drugs in the pathogenesis of gingival overgrowth: A collective review of current concepts. Periodontology 2000, Vol. 21, 1999, 176-196. 5. Michelle L, Moffitt, David E, Bencivenni, Robert E Cohen. Drug-Induced Gingival Enlargement: An Overview. Compend; CDE 2; 2013, 34: 5.
  • 63. 63 6. Brown RS, Beaver WT, Bottomley WK. On the mechanism of drug-induced gingival hyperplasia. On the mechanism of DIGH. Oral Pathol Med. 1991; 20:201-9. 7. Nyska A, M. Shemesh, H Tal, Dayan D. Gingival Hyperplasia Induced by Calcium Channel Blockers: Mode of Action. Medical Hypothesis. 1994; 43:115-118. 8. Christina Popova, Antoaneta Mlachkova. Surgical approach to drug - induced 9. gingival enlargement in renal transplant patients: Case report. J of IMAB, 2007, vol. 13, book 2. 10. Arnold D Steinberg. Clinical management of phenytoin-induced gingival overgrowth in handicapped children. Pediatric dentistry. Volume 3, Special Issue. 11. Chae HJ, Ha MS, Yun DH, Chung HT. Mechanism of Cyclosporine-induced Overgrowth in Gingiva. J Dent Res85(6):515-519, 2006.
  • 65. 65